BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36123851)

  • 1. Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report.
    Farah AM; Gu S; Jia Y
    Medicine (Baltimore); 2022 Sep; 101(37):e30666. PubMed ID: 36123851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
    Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
    Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
    Ye S; Zhou S; Wu Y; Pei X; Jiang W; Shi W; Yang W; Zhou X; Shan B; Yang H
    Ann Med; 2023 Dec; 55(1):2218104. PubMed ID: 37272300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
    Caumanns JJ; van Wijngaarden A; Kol A; Meersma GJ; Jalving M; Bernards R; van der Zee AGJ; Wisman GBA; de Jong S
    Cancer Lett; 2019 Oct; 461():102-111. PubMed ID: 31319139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.
    Oishi T; Itamochi H; Kudoh A; Nonaka M; Kato M; Nishimura M; Oumi N; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
    Oncol Rep; 2014 Aug; 32(2):553-8. PubMed ID: 24927217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.
    Caumanns JJ; Berns K; Wisman GBA; Fehrmann RSN; Tomar T; Klip H; Meersma GJ; Hijmans EM; Gennissen AMC; Duiker EW; Weening D; Itamochi H; Kluin RJC; Reyners AKL; Birrer MJ; Salvesen HB; Vergote I; van Nieuwenhuysen E; Brenton J; Braicu EI; Kupryjanczyk J; Spiewankiewicz B; Mittempergher L; Bernards R; van der Zee AGJ; de Jong S
    Clin Cancer Res; 2018 Aug; 24(16):3928-3940. PubMed ID: 29685880
    [No Abstract]   [Full Text] [Related]  

  • 7. PIK3CA gene mutations and amplifications in Chinese patients with ovarian clear cell carcinoma.
    Jiang G; Huang Z; Zhang S; Wang L
    Cancer Invest; 2013 Dec; 31(10):639-44. PubMed ID: 24299208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision medicine for ovarian clear cell carcinoma based on gene alterations.
    Kuroda T; Kohno T
    Int J Clin Oncol; 2020 Mar; 25(3):419-424. PubMed ID: 32020380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy.
    Hu X; Xia M; Wang J; Yu H; Chai J; Zhang Z; Sun Y; Su J; Sun L
    Biomed Pharmacother; 2020 Sep; 129():110397. PubMed ID: 32585451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic Significance of HNF-1β, AIRD1A, and PIK3CA Expression in Ovarian Clear Cell Carcinoma: A Tissue Microarray Study of 130 Cases.
    Ye S; Yang J; You Y; Cao D; Huang H; Wu M; Chen J; Lang J; Shen K
    Medicine (Baltimore); 2016 Mar; 95(9):e3003. PubMed ID: 26945423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations.
    Huang HN; Huang WC; Lin CH; Chiang YC; Huang HY; Kuo KT
    Hum Pathol; 2014 Nov; 45(11):2318-25. PubMed ID: 25281027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of PI3K/AKT/mTOR and MAPK signaling pathways decreases progranulin expression in ovarian clear cell carcinoma (OCCC) cell line: a potential biomarker for therapy response to signaling pathway inhibitors.
    Perez-Juarez CE; Arechavaleta-Velasco F; Zeferino-Toquero M; Alvarez-Arellano L; Estrada-Moscoso I; Diaz-Cueto L
    Med Oncol; 2019 Nov; 37(1):4. PubMed ID: 31713081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
    Takai M; Nakagawa T; Tanabe A; Terai Y; Ohmichi M; Asahi M
    Cancer Biol Ther; 2015; 16(2):325-35. PubMed ID: 25756515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer.
    Fujiwara S
    Jpn J Clin Oncol; 2023 Jul; 53(8):664-672. PubMed ID: 37288485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
    Janku F; Wheler JJ; Westin SN; Moulder SL; Naing A; Tsimberidou AM; Fu S; Falchook GS; Hong DS; Garrido-Laguna I; Luthra R; Lee JJ; Lu KH; Kurzrock R
    J Clin Oncol; 2012 Mar; 30(8):777-82. PubMed ID: 22271473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clearer view on ovarian clear cell carcinoma.
    De Pauw A; Naert E; Van de Vijver K; Philippe T; Vandecasteele K; Denys H
    Acta Clin Belg; 2022 Aug; 77(4):792-804. PubMed ID: 34404331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma.
    Murakami K; Kanto A; Sakai K; Miyagawa C; Takaya H; Nakai H; Kotani Y; Nishio K; Matsumura N
    Mod Pathol; 2021 Nov; 34(11):2071-2079. PubMed ID: 34172890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct β-catenin and PIK3CA mutation profiles in endometriosis-associated ovarian endometrioid and clear cell carcinomas.
    Matsumoto T; Yamazaki M; Takahashi H; Kajita S; Suzuki E; Tsuruta T; Saegusa M
    Am J Clin Pathol; 2015 Sep; 144(3):452-63. PubMed ID: 26276776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebellar Metastasis From Ovarian Carcinoma Harboring PIK3CA-Activating Mutation: A "Clear" Explanation for Unexpected "Vertigo".
    Piermattei A; Santoro A; Angelico G; Inzani F; Valente M; Pettinato A; Vatrano S; Scambia G; Fraggetta F; Zannoni GF
    Int J Gynecol Pathol; 2020 Jan; 39(1):68-71. PubMed ID: 30252727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.
    Kuo KT; Mao TL; Jones S; Veras E; Ayhan A; Wang TL; Glas R; Slamon D; Velculescu VE; Kuman RJ; Shih IeM
    Am J Pathol; 2009 May; 174(5):1597-601. PubMed ID: 19349352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.